Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/metformin - AstraZeneca

Drug Profile

Dapagliflozin/metformin - AstraZeneca

Alternative Names: Dapagliflozin/metformin FDC; Ebymect; Metformin/dapagliflozin; Oxramet; Xigduo XR; Xigduo XR FDC

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 27 Jun 2019 The CHMP of EMA adopts positive opinion recommending a change in already-approved indication of Type 2 diabetes mellitus
  • 28 Apr 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Russia (PO, Controlled release)
  • 13 Mar 2019 AstraZeneca completes the phase III DAPA-GDM trial for Type-2 diabetes mellitus in USA (NCT02338193)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top